L'intérêt à découvert pour Virax Biolabs Group donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Virax Biolabs Group. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Virax Biolabs Group (NASDAQ:VRAX) Stock, Rapport sur les intérêts à découvert

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Virax Biolabs Group Limited - Ordinary Shares

Virax Biolabs Group Ltd

HC Wainwright &amp; Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and lowers the price target from $14 to $12.

News

Price Target

Analyst Ratings

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $12

NTRB

Nutriband Inc. Signs Associate Partnership Deal With Charlotte FC To Boost Brand Visibility, Promote AI Tape

Rosenblatt analyst Mike Genovese upgrades Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from Neutral to Buy and lowers the price target from $115 to $85.

Upgrades

COHR

Rosenblatt Upgrades Coherent to Buy, Lowers Price Target to $85

AerCap Closes Q1 2025 With 112 Lease Deals, $1.5B Financing, And $558M Share Buyback

HC Wainwright &amp; Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and maintains $15 price target.

Reiteration

KALA

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Macro Economic Events

Economics

China Earlier Announced 34% Tariff On All U.S. Imports Starting April 10 In Response To U.S.Tariffs Imposed By President Trump

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

MSSA

Metal Sky Star To Be Delisted From Nasdaq After SPAC Deadline Miss, Will Move To OTC Market

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

UTHR

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Biotech

Health Care

General

AXSM

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

NYAX

Nayax Plans To Maintain Current Hardware Pricing For US Customers, Despite New Tariffs Imposed On Imports To US

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $30 price target.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $30 Price Target

<ul>
<li>Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year.</li>
<li>Approval brings AstraZeneca and Daiichi Sankyo's Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease.</li>
</ul>

Large Cap

The European Commission Approves AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) As Monotherapy For Adult Patients With Unresectable Or Metastatic Hormone Receptor-positive, HER2-low Or HER2-ultralow Breast Cancer Who Have Received At Least One Endocrine Therapy In The Metastatic Setting And Who Are Not Considered Suitable For Endocrine Therapy As The Next Line Of Treatment

ARVN

Arvinas Says It Presented First-in-Human Data For Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, And Central And Peripheral LRRK2 Degradation

In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
&nbsp;

The European Commission Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Adults With Resectable Non-small Cell Lung Cancer At High Risk Of Recurrence And No Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

AKBA

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $220 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $220 Price Target

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">JAKKS Pacific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>)</h3>
<ul>
<li>On March 18, Small Cap Consumer Research analyst Eric Beder reiterated Jakks Pacific with a Buy and maintained a $40 price target. The company's stock fell around 15% over the past five days and has a 52-week low of $17.06.</li>
<li>RSI Value: 25.2</li>
<li>JAKK Price Action: Shares of JAKKS Pacific fell 13.9% to close at $21.36 on Thursday.</li>
<li>Edge Stock Ratings: 39.60 Momentum score with Value at 94.24. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/JAKK"><img loading="lazy" decoding="async" width="437" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png" alt="" class="wp-image-857015" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png 437w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40-300x122.png 300w" sizes="(max-width: 437px) 100vw, 437px" /></a></figure>
<h3 class="wp-block-heading">Haverty Furniture Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 24, Haverty Furniture reported fourth-quarter financial results and beat its EPS and revenue estimates. Steven G. Burdette, President and CEO, said, &#8220;Our team remained disciplined in managing our operations and executing our growth strategies, even amidst the housing slowdown. We achieved our goal of opening five net new stores in 2024, with a notable return to the Houston, TX market after approximately 40 years, where we now have two stores.&#8221; The company's stock fell around 17% over the past month and<a href="https://www.benzinga.com/quote/HVT"> has a 52-week low </a> of $17.78.</li>
<li>RSI Value: 27.1</li>
<li>HVT Price Action: Shares of Haverty Furniture dipped 13% to close at $17.88 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">HVT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="925" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png" alt="" class="wp-image-857016" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-768x687.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<h3 class="wp-block-heading">Six Flags Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>)</h3>
<ul>
<li>On March 25, Truist Securities analyst Michael Swartz maintained Six Flags Entertainment with a Buy and lowered the price target from $56 to $52. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/FUN">low of $31.33.</a></li>
<li>RSI Value: 27.7</li>
<li>FUN Price Action: Shares of Six Flags Entertainment fell 14.4% to close at $31.98 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">FUN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="900" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png" alt="" class="wp-image-857017" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-768x711.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

JAKK

Top 3 Consumer Stocks That Are Set To Fly This Quarter

Press Releases

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Contracts

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Comments

Virax Biolabs Group

Intérêt court

Virax Biolabs Group (NASDAQ:VRAX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL